Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression signatures for combined ATO and CDDP treatment (Ato-C) in CML cell lines

ABSTRACT: Gene expression signatures for combined ATO and CDDP treatment (Ato-C) in CML cell lines

PROVIDER: PRJNA413918 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Gene expression signatures for combined ATO and CDDP treatment (Ato-C) in CML cell lines

Project description:To investigate the effect of Ato-C on gene expression, we have employed whole genome microarray expression profiling as a discovery platform to identify genes with the potential to suppress the cell proliferation of Ph+ CML cell lines. K562, KU-812 and MEG-A2 cells were treated with ATO, CDDP or Ato-C for 24 h in vitro.

2017-10-12 | GSE104813 | GEO

Comparison of the Transcriptomic Signatures in Pediatric and Adult CML

Project description:Comparison of the Transcriptomic Signatures in Pediatric and Adult CML

| PRJNA687184 | ENA

Gene expression profiles of ATO-treated and negative control cells

Project description:Gene expression profile changes between ATO- treated and DMSO- treated Huh7 and Hep3B cells were analyzed To further explore the mechanism of ATO-induced differentiation, we performed a gene microarray assay to compare the differential gene expression profiles of low-dose ATO-treated (3 μM ATO treatment for 7 days) and negative control cells.

2019-07-01 | GSE128517 | GEO

ATO and Gossypol for GSC treatment

Project description:Glioblastoma is one of the deadliest malignancies worldwide and is virtually incurable due to its highly infiltrative growth and limited sensitivity to conventional treatment by radiochemotherapy. It is hypothesized that a small population of cells with a stem-like phenotype is the major culprit of tumor recurrence. These cells are characterized by an enhanced DNA repair capacity and expression of stemness marker genes, and elimination of this population might delay or even stop tumor recurrence following radiochemotherapy. The aim of this study was to analyze whether interference with the Hedgehog signaling (Hh) pathway or combined Hh/Notch blockade can efficiently target these cancer stem cells and sensitize them to chemotherapeutic drugs. Using tumor sphere lines and primary glioma cells we demonstrate that the Hh pathway inhibitor GANT61 (GANT) and the Hh/Notch inhibitor arsenic trioxide (ATO) are capable to synergistically decrease proliferation and induce cell death in combination with the natural cotton derived anticancer agent (-)-Gossypol (Gos). In contrast to GANT in combination with Gos, the ATO/Gos combination also strongly prevented sphere formation and recovery. These synergistic effects were associated with major proteomic changes indicating decreased cell movement, distortion of cell cycle and DNA repair, as well as markedly reduced stemness. Collectively, our data show that ATO and Gos, two drugs that are safe for use in humans, represent a promising targeted therapy approach for the synergistic and specific elimination of glioma stem-like cells.

2019-03-13 | PXD009249 | Pride

H3K27 tri-methylation signature in CML CD34+ cells

Project description:This study compares the epigenetic signatures of CD34+ cells from chronic phase chronic myeloid leukemia (CML) samples and blast phase CML samples v.s. normal CD34+ cells from cord blood and adult bone marrow samples. H3K27me3 genomic loci were detected by ChIP-seq.

2021-11-08 | GSE188241 | GEO

The transcriptional response of ovarian cancer cells to treatment with cisplatin (CDDP)

2013-12-31 | GSE38545 | GEO

Human HL-60 Cells: all-trans retinoic acid (ATRA) vs. ATRA plus arsenic trioxide (ATO)

Project description:Transcriptional profiling of human leukemia?HL-60 cells comparing ATRA treated HL-60 cells with ATRA plus ATO. Goal was to determine the effects of ATO on ATRA induced differentiation of HL-60 cells. Two-condition experiment, ATRA vs. ATRA plus ATO treated HL-60 cells.

2015-03-31 | E-GEOD-67420 | biostudies-arrayexpress

The transcriptional response of ovarian cancer cells to treatment with cisplatin (CDDP)

Project description:The transcriptional response to CDDP of three ovarian cancer cell lines was studied. These lines show different genetic profiles and display different susceptibilities to CDDP. The time and doses that resulted in the apoptotic death of each cell line was identified and used to study the expression profiles associated to CDDP-induced cell death in each cell line. CDDP: cis-diamminedichloroplatinum(II) In order to elucidate the mechanism of CDDP dependent cell susceptibilities to drugs, the transcriptional response of the three ovarian cancer cell lines to CDDP were studied by microarray based transcription profiling

2013-12-31 | E-GEOD-38545 | biostudies-arrayexpress

Gene expression analysis of chronic myeloid leukemic stem cells and progenitor cells from untreated and imatinib-treated CML-like mice

Project description:To understand gene expression signatures of CML stem cells underlying imatinib-resistance, we compared transcriptomes of CML stem and progenitor cells from vehicle and imatinib-treated CML mice, respectively.

2021-05-23 | GSE175323 | GEO

ATO treatment on mesenchymal stem cells (MSCs) interacting breast cancer cells

Project description:Based on next generation RNA-seq, we examed Arsenic trioxide treatment (ATO) effect on MSCs-interacting MCF7 cells in 3D cultures. We found gap junction protein Cx43 is dramatically downregulated after ATO treatment..

2018-10-01 | GSE118923 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data